Tocilizumab, a humanized mAb specific for the α-chain of the IL-6 receptor (which prevents IL-6 from binding to membrane bound and soluble IL-6 receptors), has been recently tested in SLE patients with promising results [128]. The gene discussed is IL6; the disease is systemic lupus erythematosus.